Save Product
Product Details
Synonyms
IL-17A, Interleukin-17A, CTLA-8, IL-17, IL-17F, Interleukin-17F, Cytokine ML-1, IL17A＆IL17F
Source
Biotinylated Human IL-17A&IL-17F, Avitag,His Tag (ILF-H82W1) is expressed from human 293 cells (HEK293). It contains AA Gly 24 - Ala 155 (IL-17A) & Arg 31 - Gln 163 (IL-17F) (Accession # Q16552-1 (IL-17A) & Q96PD4-1 (IL-17F)).
Predicted N-terminus: Gly 24
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
Subunit IL-17A&IL-17F is fused with an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 34.1 kDa. The protein migrates as 40-43 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the SABA assay / HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated Human IL-17A&IL-17F, Avitag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA
Immobilized Anti-Human IL17A MAb at 2 μg/mL (100 μL/well) can bind Biotinylated Human IL-17A&IL-17F, Avitag,His Tag (Cat. No. ILF-H82W1) with a linear range of 0.2-6 ng/mL (QC tested).
Protocol
Bioactivity-BLI
Loaded Biotinylated Human IL-17A&IL-17F, Avitag,His Tag (Cat. No. ILF-H82W1) on SA Biosensor, can bind Human IL-17 RA, His Tag (Cat. No. ILA-H5222) with an affinity constant of 352 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Biotinylated Human IL-17A&IL-17F, Avitag,His Tag (Cat. No. ILF-H82W1) on SA Biosensor, can bind Human IL-17 RC, Fc Tag with an affinity constant of 217 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Background
Recent Advances
Drug Development Progress- English Name：
Interleukin-17F
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
5 Details
- Highest Development Stage：
NDA/BLA
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
